Boris C Bastian

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin
    David C Whiteman
    Cancer Control Group, Queensland Institute of Medical Research, Brisbane, QLD, Australia
    Pigment Cell Melanoma Res 24:879-97. 2011
  2. pmc KIT as a therapeutic target in metastatic melanoma
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    JAMA 305:2327-34. 2011
  3. pmc Germline mutations in BAP1 predispose to melanocytic tumors
    Thomas Wiesner
    Department of Dermatology, Medical University of Graz, Graz, Austria
    Nat Genet 43:1018-21. 2011

Collaborators

  • William J Pavan
  • David C Whiteman
  • Richard D Carvajal
  • Thomas Wiesner
  • Gabriele Palmedo
  • Michael R Speicher
  • Bartosz Chmielowski
  • Isabella Fried
  • Jerrold Teitcher
  • Rajmohan Murali
  • Klaus J Busam
  • Nancy Bouvier
  • Ruth Ann Roman
  • Heinz Kutzner
  • Jurgen C Becker
  • Klaus G Griewank
  • Naoko Takebe
  • Anne Fusco
  • Arno Rutten
  • Christian Windpassinger
  • Gary K Schwartz
  • Swapna Vemula
  • Lauren Cane
  • Arthur Ott
  • Anna C Pavlick
  • Alex E Lash
  • Mono Pirun
  • Cristina R Antonescu
  • Katherine S Panageas
  • Ingrid Wolf
  • Nicholas D Socci
  • Peter Ulz
  • Jedd D Wolchok
  • Lorenzo Cerroni
  • Shea Loy
  • Werner Wackernagel
  • Paul B Chapman
  • Anna C Obenauf
  • Jose Lutzky
  • Agnes Viale
  • David Abramson
  • Kenneth Offit

Detail Information

Publications3

  1. pmc The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin
    David C Whiteman
    Cancer Control Group, Queensland Institute of Medical Research, Brisbane, QLD, Australia
    Pigment Cell Melanoma Res 24:879-97. 2011
    ..We integrate the evidence from these separate trajectories to catalog the emerging major categories of melanomas and conclude with important unanswered questions relating to the development of melanoma and its cells of origin...
  2. pmc KIT as a therapeutic target in metastatic melanoma
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    JAMA 305:2327-34. 2011
    ..We explored the effects of KIT inhibition using imatinib mesylate in this molecular subset of disease...
  3. pmc Germline mutations in BAP1 predispose to melanocytic tumors
    Thomas Wiesner
    Department of Dermatology, Medical University of Graz, Graz, Austria
    Nat Genet 43:1018-21. 2011
    ..These findings suggest that loss of BAP1 is associated with a clinically and morphologically distinct type of melanocytic neoplasm...